TOP > 外国特許検索 > CANCER LESION TISSUE EVALUATION FOR OPTIMIZING EFFECT OF BORON NEUTRON CAPTURE THERAPY

CANCER LESION TISSUE EVALUATION FOR OPTIMIZING EFFECT OF BORON NEUTRON CAPTURE THERAPY NEW

外国特許コード F190009960
整理番号 (S2018-0339-N0)
掲載日 2019年10月25日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2019JP005727
国際公開番号 WO 2019160129
国際出願日 平成31年2月8日(2019.2.8)
国際公開日 令和元年8月22日(2019.8.22)
優先権データ
  • 特願2018-025216 (2018.2.15) JP
発明の名称 (英語) CANCER LESION TISSUE EVALUATION FOR OPTIMIZING EFFECT OF BORON NEUTRON CAPTURE THERAPY NEW
発明の概要(英語) The present invention relates to a method, a kit, etc., for predicting the response of a BNCT using a BSH-related medicine-containing boron preparation and a BPA-containing boron preparation, the method and kit being characterized by examining the expression of CD44, a translation-related factor and/or LAT1 in cancer cells of a sample. When the expression of the CD44 or translation-related factor in the cancer cells of the sample is high, it can be predicted that the BNCT using the BSH-related medicine-containing boron preparation is likely to be responsive. When the expression of the LAT1 in the cancer cells of the sample is high, it can be predicted that the BNCT using the BPA-containing boron preparation is likely to be responsive.
従来技術、競合技術の概要(英語) BACKGROUND ART
BNCT is, an agent containing boron (boron agent) is administered to the cancer patients, cancer cell selectively incorporated boron atoms, neutrons can be irradiated to the affected part by a method in which the treatment of cancer. In this method, boron in the boron atom of the neutron capture agent, α particles (helium nuclei) and split into lithium nuclei. A cancer cell by the energy of this α particles are selectively destroyed. Current, mainly boron as a p- (BPA) boronophenylalanine BNCT used drug. However, using conventional BPA BNCT sufficient results cannot be obtained has been found that the carcinoma, and may be of the so far not adapted for BNCT carcinomas are many.
In order to predict the effect of administration of the BPA, a radioactive isotope is fluorine F-BPA chemically bonded amino acids such as BPA LAT1 is in the same manner as captured from the transporter can be used to, F-BPA-PET imaging by the tissue can be evaluated by the integrated circuit is performed (see Non-Patent Document 1-5). However, can be limited to the PET imaging facility, since the price of the drug, the effect cannot be easily predicted. In addition, other than the cellular uptake of BPA boron agent evaluation has not been found an effective means.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY
  • 発明者(英語)
  • MATSUI, Hideki
  • FUJIMURA, Atsushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close